UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q/A
AMENDMENT NO. 1
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 1999
or
[ ] TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from to
------------ ----------
Commission File Number: 0-26082
VIDAMED, INC.
(exact name of registrant as specified in its charter)
Delaware 77-0314454
(State or other jurisdiction (IRS Employer Identification No.)
incorporation or organization)
46107 Landing Parkway
Fremont, CA 94538
(Address of principal executive offices)
(510) 492-4900
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days. [X] Yes [ ] No
The number of outstanding shares of the registrant's Common Stock, $.001 par
value, was 20,650,603 as of August 13, 1999.
<PAGE>
VIDAMED, INC.
<TABLE>
INDEX
PART I: FINANCIAL INFORMATION
<CAPTION>
Page
<S> <C>
Item 1. Condensed consolidated financial statements - unaudited
Condensed consolidated balance sheets - March 31, 1999
and December 31, 1998 3
Condensed consolidated statements of operations - three months
ended March 31, 1999 and 1998 4
Condensed consolidated statements of cash flows - three months
ended March 31, 1999 and 1998 5
Notes to condensed consolidated financial statements 6
Item 2. Management's discussion and analysis of financial condition
and results of operations 8
Item 3 Quantitative and qualitative Disclosure About Market Risk 13
PART II: OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K 14
Signatures 14
Page 2 of 15
</TABLE>
<PAGE>
PART I: FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
<TABLE>
VidaMed, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
<CAPTION>
March 31, December 31,
1999 1998
-------- --------
(Unaudited) (*)
<S> <C> <C>
Assets
Current Assets:
Cash and cash equivalents $ 7,816 $ 9,384
Accounts receivable 499 228
Inventories 1,020 1,228
Other current assets 1,113 1,179
-------- --------
Total current assets 10,448 12,019
Property and equipment, net 1,542 1,797
Other assets, net 318 316
-------- --------
Total assets $ 12,308 $ 14,132
======== ========
Liabilities and stockholders' equity
Current liabilities:
Notes payable, current portion $ 912 $ 764
Accounts payable 255 338
Accrued professional fees 217 317
Accrued clinical trial costs 320 431
Accrued and other liabilities 2,650 2,362
Accrued advertising costs 309 309
Restructuring accrual 252 252
Current portion of obligations under capital leases -- 22
Deferred revenue 231 229
-------- --------
Total current liabilities 5,146 5,024
Notes payable, long-term portion 1,607 1,785
Stockholders' equity:
Capital stock 96,930 95,542
Accumulated deficit (91,375) (88,219)
-------- --------
Total stockholders' equity 5,555 7,323
-------- --------
Total liabilities and stockholders' equity $ 12,308 $ 14,132
======== ========
<FN>
* The Balance Sheet at December 31, 1998 has been derived from the audited financial statements at
that date but does not include all of the information and footnotes required by generally accepted
accounting principles for complete financial statements.
See accompanying notes.
</FN>
</TABLE>
Page 3 of 15
<PAGE>
VidaMed, Inc.
Condensed Consolidated Statements of Operations
(In thousands except per share amounts)
(Unaudited)
Three Months Ended
March 31,
-------------------------
1999 1998
-------- --------
Revenues:
Product sales, net $ 987 $ 1,375
License fees and grant revenue 50 289
-------- --------
Net revenues 1,037 1,664
Cost of Products Sold 833 1,072
-------- --------
Gross Profit 204 592
Operating Expenses:
Research and development 814 1,132
Selling, general and administrative 2,504 4,607
-------- --------
Total operating expenses 3,318 5,739
-------- --------
Loss from operations (3,114) (5,147)
Other income(expense), net (42) (91)
-------- --------
Net loss $ (3,156) $ (5,238)
======== ========
Basic and diluted net loss per share $ (0.16) $ (0.34)
======== ========
Shares used in computing basic and diluted
net loss per share 20,313 15,238
======== ========
See accompanying notes.
Page 4 of 15
<PAGE>
<TABLE>
VidaMed, Inc.
Condensed Consolidated Statement of Cash Flows
(In thousands)
(Unaudited)
<CAPTION>
Three Months Ended
March 31,
------------------------
1999 1998
------- -------
<S> <C> <C>
Cash flows from operating activities:
Net loss $(3,156) $(5,238)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization 313 348
Changes in assets and liabilities:
Accounts receivable (271) 452
Inventory 208 (7)
Other current assets 66 (762)
Other assets (2) (2)
Accounts payable (83) (347)
Accrued professional fees (100) (163)
Accrued clinical trial costs (111) (29)
Accrued interest payable -- (568)
Accrued and other liabilities 288 1,118
Deferred revenue 2 (235)
------- -------
Net cash used in operating activities (2,846) (5,395)
------- -------
Cash flows from investing activities:
Expenditures for property and equipment (58) (504)
Net cash used in investing activities (58) (504)
------- -------
Cash flows from financing activities:
Principal payments under capital leases (22) (38)
Principal payments of notes payable (30) (303)
Net proceeds from issuance of notes payable -- 1,500
Net proceeds from issuance of common stock 1,388 52
------- -------
Net cash provided by financing activities 1,336 1,211
------- -------
Net decrease in cash and cash equivalents (1,568) (4,688)
Cash and cash equivalents at the beginning
of the period 9,384 8,026
------- -------
Cash and cash equivalents at the end of the period $ 7,816 $ 3,338
======= =======
Supplemental disclosure of cash flows information:
Cash paid for interest $ 95 $ 98
======= =======
<FN>
See accompanying notes.
</FN>
</TABLE>
Page 5 of 15
<PAGE>
VIDAMED, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
March 31, 1999
(Unaudited)
1. Basis of presentation
The accompanying unaudited condensed consolidated financial statements of
VidaMed, Inc. (the "Company" or "VidaMed") have been prepared in accordance with
generally accepted accounting principles for interim financial information and
with the instructions for Form 10-Q and Article 10 of Regulation S-X. The
balance sheet as of March 31, 1999 and the statements of operations for the
three months ended March 31, 1999 and 1998, and the statements of cash flows for
the three months ended March 31, 1999 and 1998, are unaudited but include all
adjustments (consisting of normal recurring adjustments) which the Company
considers necessary for a fair presentation of the financial position at such
date and the operating results and cash flows for those periods. Although the
Company believes that the disclosures in these financial statements are adequate
to make the information presented not misleading, certain information normally
included in financial statements and related footnotes prepared in accordance
with generally accepted accounting principles have been condensed or omitted
pursuant to the rules and regulations of the Securities and Exchange Commission.
The accompanying financial statements should be read in conjunction with the
financial statements and notes thereto included in the Company's annual report
on Form 10-K, as amended, for the year ended December 31, 1998 filed with the
Securities and Exchange Commission.
Results for any interim period are not necessarily indicative of results for any
other interim period or for the entire year.
2. Net loss per share
The Company calculates net loss per share in accordance with Statement of
Financial Accounting Standards No. 128, "Earnings per Share." Statement 128
requires the presentation of basic earnings (loss) per share and diluted
earnings (loss) per share, if more dilutive, for all periods presented. Basic
and diluted net loss per share are computed using the weighted-average number of
shares of common stock outstanding during the periods presented. Securities that
could share in the earnings of the Company, such as options, warrants and
convertible securities, are excluded from the computation, as their effect is
anti-dilutive. As the Company has incurred losses from operations in each of the
periods presented, there is no difference between basic and diluted net loss per
share amounts.
3. Inventories
Inventories are stated at the lower of cost (determined using the first-in,
first-out method) or market value. The decrease in inventory from December 31,
1998, through March 31, 1999, is due primarily to sales of finished goods
inventory and the Company not undertaking to manufacture additional inventory at
this time
Page 6 of 15
<PAGE>
due to a planned surplus of finished goods. Inventories at March 31, 1999 and
December 31, 1998 consist of the following (in thousands):
March 31, December 31,
1999 1998
------ -------
Raw materials $ 260 $ 404
Work in process 208 261
Finished goods 552 563
------ -------
$1,020 $1,228
====== =======
4. Notes Payable
During 1998, the Company finalized a commitment for $5.5 million in new debt
financing with Transamerica Technology Finance, a division of Transamerica
Corporation. The facility is secured by the Company's assets and consists of a
revolving accounts receivable-based credit line of up to $3 million and a $2.5
million equipment term loan. The term loan was funded in full as of December 31,
1998, at an interest rate of 12% per year. Repayment of that loan is amortized
over a three-year period, with the first monthly payment having been made in
December 1998 and continuing monthly thereafter.
As of March 31, 1999, the Company borrowed approximately $335,000 against the
revolving accounts receivable-based line at a rate of 9.75% per year. It was
eligible to borrow approximately $358,000 against this line on March31, 1999,
and borrowed the remaining available balance of approximately $23,000 in April
1999.
5. Restructuring Accrual
In September 1997, VidaMed announced a restructuring program designed to reduce
costs and improve operating efficiencies by closing the company's U.K.
manufacturing facility. The charge in the third quarter of 1997 was $2.1
million.
The elements of the total charge as of March 31, 1999 are as follows (in
thousands):
Representing
----------------------------------------
Cash Outlays
------------------
Total Asset
Charges Write-down Completed Future
Fixed assets $ 390 $ 390 $ -- $ --
Facility shut down 1,305 -- 1,305 --
Grant repayment 405 -- 153 252
------ ------ ------ ------
Total Special Charges $2,100 $ 390 $1,458 $ 252
------ ------ ------ ------
6. Reporting Comprehensive Income (Loss)
As of January 1, 1998, the Company adopted Statement of Financial Accounting
Standards No.130, Reporting Comprehensive Income (Statement 130). Statement 130
establishes new rules for the reporting and display of comprehensive income and
its components. Statement 130 requires unrealized gains or
Page 7 of 15
<PAGE>
losses on the Company's available-for-sale securities and foreign currency
translation adjustments, which prior to adoption were reported in shareholders'
equity, to be included in other comprehensive income (loss). During the three
months ended March 31, 1999 and 1998, the total comprehensive loss was not
materially different from the net loss.
7. Common Stock
On December 17, 1998, the Company entered into an agreement to sell 368,596
shares of its common stock to the principals of Telo Electronics, one of our
manufacturers. The purchase price of the common stock was $2.713, the average
closing price of the common stock for the five trading days preceding December
17, 1998. The common stock was paid for with promissory notes delivered on
December 17, 1998. The transaction closed in February 1999 when the promissory
notes plus interest were paid. The Company received net proceeds of $1,000,000
from that transaction.
Total proceeds from the issuance of common stock for the quarter ended March 31,
1999 were $1,388,000. The balance of $388,000 was attributable to employee stock
plans.
8. Retention Agreements
In October 1998, the Company entered into retention agreements with certain
executive officers. Under those agreements, the Company was obligated to pay up
to $810,000 on April 1,1999, if those officers remained with the Company through
April 1, 1999. If any of those officers left the Company prior to April 1, 1999,
the amount of the obligation would decease. All officers covered by the
retention agreements remained with the Company through April 1, 1999, and the
Company paid $810,000 according to the terms of the agreements.
ITEM 2.
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following is a discussion and analysis of VidaMed's consolidated financial
condition and results of operations for the three months ended March 31, 1999
and 1998. We also discuss certain factors that may affect our prospective
financial condition and results of operations. This section should be read in
conjunction with the Condensed Consolidated Financial Statements and related
Notes in Item 1 of this report and the Company's Annual Report on Form 10-K, as
amended, for the year ended December 31, 1998, which has been filed with the
Securities and Exchange Commission and is available from the Company at no
charge.
Cautionary Statement Regarding Forward-Looking Statements
This Management's Discussion and Analysis of Financial Condition and Results of
Operations contains, in addition to historical information, forward-looking
statements that are based on VidaMed's current expectations, beliefs, intentions
or future strategies. The forward-looking statements concern, among other
things, the availability of cash resources to fund continued operations and
market acceptance of and the likelihood of additional Medicare reimbursement
coverage for the TUNA Procedure. We base all forward-looking statements on
information available to us on the date of this report. We do not undertake to
update any such forward-looking statements to reflect events that arise after
the date of this report. Actual results could differ materially from those in
the forward-looking statements because of the factors described under
Page 8 of 15
<PAGE>
"Liquidity and Capital Resources" and "Risk Factors" in this report and in our
annual report on Form 10-K, as amended, for the year ended December 31, 1998.
Overview
We design, develop, and market urological systems that are used for urinary
tract disorders. We primarily treat the enlarged prostate or Benign Prostatic
Hyperplasia ("BPH"), a noncancerous condition of the prostrate gland affecting
urination. VidaMed's primary product, the patented VidaMed TUNA System, is a
reasonably priced alternative therapy that minimizes surgical invasion, side
effects and complications for this condition. In the United States, we sell our
products primarily through direct sales personnel. Internationally, we primarily
sell to distributors who resell to physicians and hospitals.
At the beginning of fiscal 1999, we began restructuring our United States sales
and marketing model to align with current hospital-based reimbursement coverage.
Under the prior model, we focused on selling the TUNA System generator and
related equipment to hospitals, physician groups and ambulatory service centers
("ASC"). Under the new sales model, an entire TUNA System is placed with a
hospital at no initial capital charge, and a per use fee is charged for each
procedure performed.
We received FDA clearance to market the TUNA System in 1996. In 1998, Medicare
reimbursement coverage became available for procedures using our equipment that
are performed in hospitals. As of March 31, 1999, 30 states provided such
reimbursement coverage. To achieve significant increases in sales, we must
actively promote the fee-per-use program and secure Medicare reimbursement
coverage at least in all states with large populations of men over 50 years of
age, which is our target patient population. The Company has several initiatives
underway to facilitate the Medicare reimbursement coverage process, including
working in cooperation with state Medicare Medical Directors. Notwithstanding
the foregoing, there can be no assurance that the Company will receive
additional Medicare reimbursement coverage in major states in a timely manner,
and the failure to receive such coverage would have a material adverse effect on
the business, financial condition and results of operations of the Company.
Medicare coverage for supplies and devices in the office-based and ASC markets
was delayed in mid-1998 due to Medicare's review of its "Year 2000" compliance.
We believe that Medicare reimbursement in doctors' offices and ASCs, as well as
patient awareness and physician advocacy of the TUNA System and procedure, are
our greatest challenges. Our business strategy is to focus marketing and sales
efforts on patient education and physician support for our fee-per-use program
while at the same time continue to advance Medicare reimbursement for the TUNA
Procedure, but, as discussed below in "Liquidity and Capital Resources," we will
not be able to do so without additional debt or equity financing.
Although initial results from our fee-per-use sales model are favorable, we do
not anticipate reaching profitability in the near future. We expect our
operating losses to continue as we commit substantial resources to expand
marketing and sales activities, fund clinical trials in support of regulatory
and reimbursement approvals, and fund research and development. Our future
profitability will be dependent upon, among other factors, market acceptance of
the VidaMed TUNA Procedure, availability and timing of third-party reimbursement
for procedures performed with the TUNA System, adoption of our fee-per-use
program and our ability to fund operations absent sufficient sales of our
products.
There can be no assurance that the TUNA System will continue to be deemed
clinically or cost effective by health care providers and payors, superior to
other current and emerging methods for treating BPH, or that the TUNA System
will achieve significant market acceptance in the United States. Furthermore,
Page 9 of 15
<PAGE>
determinations of reimbursement of the TUNA Procedure by private and
governmental health payors are made by such payors and their medical directors
independent of the FDA approval. Accordingly, there can be no assurance that the
TUNA Procedure will be reimbursed at adequate levels or continue to be
reimbursed at adequate levels in the United States under either private or
governmental healthcare payment systems. Both lack of coverage and inadequate
reimbursement for the TUNA Procedure could adversely affect market acceptance of
the TUNA System. Failure of the TUNA Procedure to achieve market acceptance in
the United States, lack of adequate funding, the impact of competitive products
and pricing and other risks could have a material adverse effect on our
business, financial condition and results of operations.
Results of Operations
Net revenue for the three months ended March 31, 1999 was $1.0 million. This was
down $0.7 million or 41% from $1.7 million in the three months ended March 31,
1998. The decrease in net revenue is primarily due to a $500,000 stocking order
from Century Medical, Inc., our Japanese distributor, in the first quarter of
1998.
United States sales of $577,000 in the first quarter of 1999 are down from sales
of $698,000 in the first quarter of 1998 due to the change in the sales model
described above in the Overview.
Cost of product sold for the three months ended March 31, 1999 was $0.8 million,
a decrease of 22% or $0.3 million from $1.1 million for the three months ended
March 31, 1998. The decrease is due to lower product sales. Also included in
cost of products sold for the three months ended March 31, 1999 were charges
related to a reduction in work force, due to the announced outsourcing of the
manufacturing of the Company's disposable product. Those charges were not
material and did not have a material effect on liquidity.
Research and development (R & D) expenses included expenditures for regulatory
compliance and clinical trials. Clinical trial costs consist largely of payments
to clinical investigators, product for clinical trials, and costs associated
with initiating and monitoring clinical trials. R&D expenses decreased 28% to
$0.8 million in the three months ended March 31, 1999 from $1.1 million in the
three months ended March 31, 1998. The decrease was primarily reduced clinical
activity in 1999.
Selling, general and administrative (SG&A) expenses decreased 46% to $2.5
million in the three months ended March 31, 1999 from $4.6 in the three months
ended March 31, 1998. The expenditures in 1998 included charges to the allowance
for doubtful accounts, as a result of the length of time involved in obtaining
Medicare reimbursement coverage for each state, the transition to a new CEO, and
a higher level of general and administrative spending.
Other expense for the three months ended March 31, 1999 was $42,000 compared to
$91,000 for the comparable period in 1998. These changes were primarily a
function of the balance of cash, cash equivalents and debt, the interest earned
or incurred, respectively, and fluctuations in the relative balances.
Our results of operations have fluctuated in the past and may fluctuate in the
future from year to year as well as from quarter to quarter. Revenues may
fluctuate as a result of several factors, including:
o Actions relating to regulatory and reimbursement matters;
o Results of clinical trials;
Page 10 of 15
<PAGE>
o The extent to which the TUNA System gains market acceptance;
o Varying pricing promotions;
o Volume discounts to customers; and
o Introduction of new products and the competitive introduction of
alternative therapies for BPH.
Operating expenses may fluctuate as a result of several factors, including:
o The timing of expansion of sales and marketing activities;
o Costs of clinical activities; and
o R&D and SG&A expenses associated with the potential growth of our
organization.
Fluctuations in operating results could have a material adverse affect on our
business by, among other things, disrupting our cash flow, limiting our ability
to attract investors, and impairing our ability to implement long range plans.
As a result, there can be no assurance as to when or whether we will achieve
profitability. If profitability is achieved, there can be no assurance such
profitability will continue in the future.
Liquidity and Capital Resources
At March 31, 1999, the Company's cash and cash equivalents decreased $1.6
million to $7.8 million, compared to $9.4 million at December 31,1998. The
decrease is due to operating expenses offset by the issuance of equity as
discussed in footnote 7. In April 1999, pursuant to retention agreements with
certain executives, which expired in April, the Company paid the executives the
aggregate of $0.8 million as discussed in footnote 8.
As we began fiscal 1999, we believed that our current cash balances, projected
cash flows from operations including a U.S. procedure based sales program (the
"fee-per-use program") and cash available under the Transamerica financing
facility would be sufficient to meet our current operating and capital
requirements through the end of the fiscal year. We now believe that the
fee-per-use program will take longer to implement than originally planned. In an
effort to increase revenues, we believe that it is necessary to:
o Increase consumer awareness of the treatment options available to
BPH patients with the view that an informed patient and his doctor
are more likely to choose the TUNA procedure;
o Provide opportunities for our field organization to increase the
number of physicians who perform TUNA Procedures; and
o Implement marketing initiatives to assist physicians build their
practices by increasing the number of TUNA Procedures performed.
The increased costs associated with this three-pronged approach together with
lower than anticipated revenues from the fee-per-use program will require us to
obtain additional financing to meet our current operating and capital
requirements through the end of the fiscal year. Management is pursuing, and
believes it can obtain, financing to fund operations through the end of this
fiscal year and into fiscal year 2000. Additional financing will likely be
required in order to fund operations throughout fiscal 2000.
We cannot give any assurance that we will be successful in securing any debt or
equity financing, or that such financing, if available, will be on favorable
terms. Any future equity financing would result in dilution to our stockholders.
If we are unable to secure additional financing this year, we would not be able
to
Page 11 of 15
<PAGE>
continue as a going concern. We would be forced to explore strategic
relationships, reduce staff and discontinue clinical trials, research and
development and marketing and sales activities.
During 1998, we finalized a commitment for $5.5 million in new debt financing
with Transamerica Technology Finance, a division of Transamerica Corporation.
The facility is secured by our assets and consists of a revolving accounts
receivable-based credit line of up to $3 million and a $2.5 million equipment
term loan. The term loan was funded in full as of December 31, 1998, at an
interest rate of 12% per year. Repayment of that loan is amortized over a
three-year period, with the first monthly payment having been made in December
1998 and continuing monthly thereafter.
As of March 31, 1999, we borrowed approximately $335,000 against the revolving
accounts receivable-based line at a rate of 9.75% per year. We were eligible to
borrow approximately $358,000 against this line on March 31, 1999, and borrowed
the remaining available balance of approximately $23,000 in April 1999.
Restructuring Accrual
In September 1997, VidaMed announced a restructuring program designed to reduce
costs and improve operating efficiencies by closing the Company's U.K.
manufacturing facility. The Company expects to incur approximately $252,000 in
cash outlays during 1999. See also Note 5 of notes to condensed consolidated
financial statements.
Impact of Year 2000
Many currently installed computer systems and software products are coded to
accept, store, or report only two digit year entries in date code fields.
Beginning in the Year 2000 (Y2K), these date code fields will need to accept
four digit entries to distinguish 21st century dates from 20th century dates.
The Y2K issue is a result of these programs being written with two digits
instead of four. As a result, computer systems and software used by companies,
including us and our vendors and customers, will need to comply with the Y2K
requirements. We presently believe that as a byproduct of normal business system
modifications and upgrades and the short length of time we have been in
operation, the Y2K issue should not have a material effect on our current
financial position, liquidity or results of operations. However, this does not
completely prevent the possibility of problems arising related to the Y2K issue
that could have a material impact on our operations.
We have been proactive in addressing the Y2K issue internally and externally.
Our primary software system is currently Y2K compliant. We do not depend on
in-house custom systems and generally purchase off-the-shelf software from
reputable vendors who have tested their software for Y2K compliance. The Y2K
issue is being considered for all future software purchases. Although we believe
the Y2K issue will not pose material operational problems for our computer
systems, there can be no assurance that problems arising from the Y2K issue will
be completely eliminated.
We have initiated communication with our significant suppliers and customers to
determine the extent to which our operations are vulnerable to a failure of any
of those third parties to remediate their own Y2K issues. The Company determined
that Medicare coverage for supplies and devices in the office-based and ASC
markets was delayed in mid-1998 due to Medicare announced Y2K problems. The ASC
reimbursement program, which was expected to be effective January 1, 1999 is not
likely to be effective before June 30, 2000. As a result of the Medicare
coverage delays, the Company established a $2.7 million reserve in the third
quarter of 1998 for all office-based and ASC sales. Other than issues related to
Page 12 of 15
<PAGE>
Medicare, none of our significant suppliers or large customers has notified us
that they have significant Y2K problems. Even where assurances are received from
third parties, however, there remains a risk that failure of systems and
products of other companies on which we rely could have a material adverse
effect on our business.
Our products are Y2K compliant and are able to operate in the Year 2000 and
beyond. There are two processors used in the TUNA System generator. One
processor does not have date sensitivity while the other does. We have tested
the date sensitive processor and have concluded that it has no significant Y2K
problems.
We believe we have an effective program in place to resolve Y2K issues in a
timely manner. We also have contingency plans for certain critical applications
and are working on such plans for others. These contingency plans involve, among
other actions:
o Manual workarounds (e.g. manual preparation of invoices, paychecks)
o Adjusting staffing strategies.
In the event that we do not completely resolve all of the Y2K issues, our
business operations could be adversely affected. Although the resulting costs
and loss of business cannot be reasonably estimated at this time, we have not
and do not expect to have material costs associated with the Y2K issues.
The most reasonably likely worst case scenario relates to our ability to use our
computerized manufacturing and accounting system. Although the software product
is Y2K compliant, other unforeseen factors could render it inoperative, such as
the inability of public utilities to provide service. This occurrence could
materially adversely effect our business. We could also be required to manually
prepare documents, such as shipping documents, invoices and checks and the like.
Such tasks would be more time consuming and would likely require additional
human resources to complete.
Item 3
Quantitative and Qualitative Disclosures About Market Risk
We are exposed to interest rate risk on the investments of our excess cash. The
primary objective of our investment activities is to preserve principal while at
the same time maximize yields without significantly increasing risk. To achieve
this objective, we invest in highly liquid and high quality debt securities. To
minimize the exposure due to adverse shifts in interest rates, we invest in
short-term securities with maturities of less than one year. Due to the nature
of our short-term investments, we have concluded that we doe not have a material
market risk exposure.
Page 13 of 15
<PAGE>
VIDAMED, INC.
PART II: OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K
a) Exhibits
(27.1) Financial Data Schedule
b) Reports on Form 8-K.
No reports on Form 8-K were filed during the quarter ended
March 31, 1999.
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto.
VIDAMED, INC.
Date: August 26, 1999 By: /s/ Randy Lindholm
--------------------------- ------------------------------
Randy Lindholm
President, Chief Executive
Officer
Date: August 26, 1999 By: /s/ John F. Howe
-------------------------- -------------------------------
John F. Howe
VP Finance, Chief Financial
Officer
(Principal Financial and
Accounting Officer)
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1999
<PERIOD-START> JAN-01-1999
<PERIOD-END> MAR-31-1999
<CASH> 7,816
<SECURITIES> 0
<RECEIVABLES> 3,562
<ALLOWANCES> 3,063
<INVENTORY> 1,020
<CURRENT-ASSETS> 10,448
<PP&E> 6,100
<DEPRECIATION> 4,558
<TOTAL-ASSETS> 12,308
<CURRENT-LIABILITIES> 5,146
<BONDS> 0
0
0
<COMMON> 20
<OTHER-SE> 5,535
<TOTAL-LIABILITY-AND-EQUITY> 12,308
<SALES> 987
<TOTAL-REVENUES> 1,037
<CGS> 833
<TOTAL-COSTS> 833
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 42
<INCOME-PRETAX> (3,156)
<INCOME-TAX> 0
<INCOME-CONTINUING> (3,156)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (3,156)
<EPS-BASIC> (.16)
<EPS-DILUTED> (.16)
</TABLE>
